Cassava Sciences engages in developing proprietary drugs for patients and healthcare professionals, and focuses its drug development efforts on disorders of the nervous system, such as chronic pain. Co.'s primary drug candidate, REMOXY, is a proprietary, abuse-deterrent, oral formulation of oxycodone developed to make oxycodone difficult to abuse yet provide pain relief. Co.'s other drug candidate, FENROCK, is a proprietary, abuse-deterrent skin patch to treat severe pain. In addition, Co. has worldwide rights to PTI-125, a small molecule drug candidate designed to treat Alzheimer's Disease and other neurological disorders. We show 7 historical shares outstanding datapoints in our PTIE shares outstanding history coverage, used to compute PTIE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PTIE market cap history over the course of time is important for investors
interested in comparing PTIE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PTIE versus a peer is one thing; comparing
PTIE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PTIE can fluctuate over the course of history.
With this page we aim to empower investors researching PTIE by allowing them to research the PTIE market cap history. |
Free PTIE Email Alerts:
Video: The Importance of Market Cap
